We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Everolimus‐associated focal segmental glomerulosclerosis in a liver transplant recipient.
- Authors
Manabe, Shun; Ino, Ayami; Miyabe, Yoei; Taneda, Sekiko; Kataoka, Hiroshi; Mochizuki, Toshio; Nitta, Kosaku
- Abstract
The kidney biopsy specimen contained 23 glomeruli, with seven having global sclerosis. The mammalian target of rapamycin (mTOR) inhibitor everolimus is considered to be a non-nephrotoxic immunosuppressant, which may become a substitute of potentially nephrotoxic calcineurin inhibitors (CNIs).1 Here, we report a rapid decline of renal function and nephrosis after initiating everolimus in a liver transplant recipient. 2 De Simone P, Saliba F, Dong G, Escrig C, Fischer L. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?.
- Subjects
EVEROLIMUS; FOCAL segmental glomerulosclerosis; LIVER transplantation
- Publication
Nephrology, 2021, Vol 26, Issue 4, p371
- ISSN
1320-5358
- Publication type
Article
- DOI
10.1111/nep.13812